Table 1.
Epidemiological, clinical and pathological patterns of patients diagnosed with endometrial cancer (n = 120).
| Pre-Pandemic (2019) | Pandemic with High Restrictions (2020) |
Pandemic Recovery (2021) | p | |
|---|---|---|---|---|
| Number of patients, n | 36 | 37 | 47 | |
| Age at diagnosis, median (IQR; Min-Max), years | 73.5 (13; 47–88) | 66.0 (15; 35–86) | 69.0 (15; 50–84) | 0.046 * |
| Postmenopausal status, n (%) | 35 (97.2) | 34 (91.9) | 46 (97.9) | 0.349 |
|
Histological type, n (%) Endometrioid Serous Clear cells Undifferentiated Carcinosarcoma Mixed |
17 (47.2) 15 (41.7) 0 (0.0) 1 (2.8) 2 (5.5) 1 (2.8) |
30 (81.1) 2 (5.4) 3 (8.1) 1 (2.7) 0 (0.0) 1 (2.7) |
34 (72.3) 3 (6.4) 1 (2.1) 3 (6.4) 2 (4.3) 4 (8.5) |
0.001 * |
|
Tumor staging 1, n (%) Initial stage (I-II) Advanced stage (III-IV) |
23 (63.9) 13 (36.1) |
32 (86.5) 5 (13.5) |
38 (80.9) 9 (19.1) |
0.054 |
| Time between first MDTM and treatment initiation, median (IQR; Min-Max), days | 23.0 (21; 6–55) | 34.0 (22; 5–76) | 36.0 (25; 13–147) | 0.002 * |
| Neoadjuvant therapy, n (%) | 0 (0.0) | 1 (2.7) | 0 (0.0) | 0.323 |
|
Surgical approach Laparoscopy, n (%) Laparotomy, n (%) Laparotomy preceded by diagnostic laparoscopy, n (%) |
9 (32.1) 18 (64.3) 1 (3.6) |
5 (14.3) 25 (71.4) 5 (14.3) |
16 (36.4) 216 (36.4) 12 (27.3) |
0.006 * |
| SLN biopsy, n (%) | 0 (0.0) | 4 (11.1) | 24 (54.5) | <0.001 * |
| Hospitalization days, median (IQR; Min-Max) | 6.5 (4; 2–29) | 6.0 (4; 2–41) | 5.0 (4; 2–23) | 0.158 |
| Intra- and post-operative complications 2, n (%) | 3 (10.7) | 3 (11.5) | 11 (25.6) | 0.176 |
| Time between surgery and histological assessment, median (IQR; Min-Max), days | 28.0 (14; 8–44) | 20.0 (11; 6–63) | 16.0 (15; 7–42) | 0.007 * |
| Time between surgery and adjuvant therapy, median (IQR; Min-Max), days | 76.0 (20; 41–194) | 63.5 (14; 35–103) | 71 (29; 3–160) | 0.314 |
Legend: IQR—interquartile range; MDTM—multidisciplinary team meeting; SLN—sentinel lymph node. 1 Tumor staging was surgical in most cases, considering the revised International Federation of Gynecology and Obstetrics (FIGO) Classification 2009; when surgery was contraindicated, clinical staging was assessed on the basis of FIGO Classification 1971 [19]. 2 Pre-pandemic (2019): infection and dehiscence of the surgical wound (n = 3); pandemic with high restrictions (2020): hemoperitoneum (n = 1), abdominal hematoma with aponeurotic dehiscence (n = 1), bladder injury (n = 1); pandemic recovery (2021): vesical dysfunction (n = 1), pelvic hematoma/abscess (n = 3), paralytic ileus (n = 1), ureter/bladder/vascular injury (n = 3), aponeurotic dehiscence (n = 2), pulmonary thromboembolism (n = 1). * Statistically significant differences for a significance level of 0.05.